Porton Advanced and Eureka Therapeutics Collaborate on CAR-T Manufacturing

• Porton Advanced has partnered with Eureka Therapeutics to advance global clinical development of novel T-cell therapies.

• The collaboration will leverage Porton Advanced’s CDMO expertise to support Eureka’s CAR-T manufacturing for investigator-initiated trials (IITs).

Porton Advanced, a contract development and manufacturing organisation (CDMO) specialising in advanced therapy medicinal products (ATMPs), has announced a partnership with Eureka Therapeutics, a clinical-stage biotechnology company focused on novel T-cell therapies for solid tumours and blood cancers. The collaboration aims to accelerate Eureka’s clinical pipeline by utilising Porton Advanced’s global manufacturing expertise.

Eureka Therapeutics, based in the San Francisco Bay Area, develops innovative T-cell therapies using its proprietary ARTEMIS® cell receptor and E-ALPHA® antibody discovery platforms. Under the partnership, Porton Advanced will provide CAR-T manufacturing services for Eureka’s Investigator-Initiated Trials (IITs), ensuring compliance with stringent quality standards at its GMP facilities.

Oliver Ju, Chairman of Porton Advanced, stated: “We are delighted to establish our partnership with Eureka. The seamless completion of the initial part of our collaboration program underscores our team’s operational excellence and commitment to quality.”

Porton Advanced has supported over 60 ATMP clinical, IND, and IIT projects in China, with more than 140 IIT batches successfully released. The company’s GMP-compliant facilities, meeting US, EU, and China standards, position it as a strategic partner for international biotech firms seeking reliable CDMO services.